NASDAQ:URGN UroGen Pharma (URGN) Stock Price, News & Analysis $11.90 -0.23 (-1.90%) Closing price 04:00 PM EasternExtended Trading$12.14 +0.24 (+2.02%) As of 04:37 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock About UroGen Pharma Stock (NASDAQ:URGN) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get UroGen Pharma alerts:Sign Up Key Stats Today's Range$11.77▼$12.3750-Day Range$9.27▼$12.1352-Week Range$9.03▼$20.70Volume364,524 shsAverage Volume491,784 shsMarket Capitalization$548.52 millionP/E RatioN/ADividend YieldN/APrice Target$38.20Consensus RatingBuy Company OverviewUroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution. The company's lead product candidate is UGN-102 for the treatment of several forms of non-muscle invasive urothelial cancer that include low-grade upper tract urothelial cancer and low-grade intermediate risk non-muscle invasive bladder cancer (NMIBC). It is also developing UGN-301 for the treatment of high-grade NMIBC. The company has license agreement with Agenus Inc. to develop, make, use, sell, import, and commercialize products of Agenus for the treatment of cancers of the urinary tract via intravesical delivery; strategic research collaboration agreement with MD Anderson focusing on the sequential use of UGN-201 and UGN-301 for the treatment of NMIBC; and licensing and supply agreement with medac Gesellschaft für klinische Spezialpräparate m.b.H. to develop UGN-103 in low-grade intermediate risk NMIBC and UGN-104 in low-grade upper tract urothelial carcinoma. UroGen Pharma Ltd. was incorporated in 2004 and is based in Princeton, New Jersey.Read More… Remove Ads UroGen Pharma Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks80th Percentile Overall ScoreURGN MarketRank™: UroGen Pharma scored higher than 80% of companies evaluated by MarketBeat, and ranked 197th out of 934 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.6 / 5Analyst RatingBuy Consensus RatingUroGen Pharma has received a consensus rating of Buy. The company's average rating score is 3.17, and is based on 5 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageUroGen Pharma has only been the subject of 3 research reports in the past 90 days.Read more about UroGen Pharma's stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for UroGen Pharma are expected to decrease in the coming year, from ($3.12) to ($3.14) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of UroGen Pharma is -3.78, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of UroGen Pharma is -3.78, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Read more about UroGen Pharma's valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted27.50% of the float of UroGen Pharma has been sold short.Short Interest Ratio / Days to CoverUroGen Pharma has a short interest ratio ("days to cover") of 15.7, which indicates bearish sentiment.Change versus previous monthShort interest in UroGen Pharma has recently decreased by 1.13%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldUroGen Pharma does not currently pay a dividend.Dividend GrowthUroGen Pharma does not have a long track record of dividend growth. Sustainability and ESG4.5 / 5Environmental Score-1.33 Percentage of Shares Shorted27.50% of the float of UroGen Pharma has been sold short.Short Interest Ratio / Days to CoverUroGen Pharma has a short interest ratio ("days to cover") of 15.7, which indicates bearish sentiment.Change versus previous monthShort interest in UroGen Pharma has recently decreased by 1.13%, indicating that investor sentiment is improving. News and Social Media3.3 / 5News Sentiment0.88 News SentimentUroGen Pharma has a news sentiment score of 0.88. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.63 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 4 news articles for UroGen Pharma this week, compared to 3 articles on an average week.Search Interest5 people have searched for URGN on MarketBeat in the last 30 days. This is an increase of 25% compared to the previous 30 days.MarketBeat FollowsOnly 4 people have added UroGen Pharma to their MarketBeat watchlist in the last 30 days. This is a decrease of -33% compared to the previous 30 days. Company Ownership2.5 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, UroGen Pharma insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $132,900.00 in company stock.Percentage Held by InsidersOnly 5.10% of the stock of UroGen Pharma is held by insiders.Percentage Held by Institutions91.29% of the stock of UroGen Pharma is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about UroGen Pharma's insider trading history. Receive URGN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for UroGen Pharma and its competitors with MarketBeat's FREE daily newsletter. Email Address URGN Stock News HeadlinesUroGen Pharma Ltd. (NASDAQ:URGN) Receives $38.20 Consensus Price Target from BrokeragesMarch 19, 2025 | americanbankingnews.comHC Wainwright Lowers Earnings Estimates for UroGen PharmaMarch 14, 2025 | americanbankingnews.comWhat Trump’s planning nextTrump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to move your money now.March 24, 2025 | Porter & Company (Ad)UroGen Pharma price target lowered to $55 from $64 at H.C. WainwrightMarch 11, 2025 | markets.businessinsider.comUroGen Pharma Ltd. (NASDAQ:URGN) Q4 2024 Earnings Call TranscriptMarch 11, 2025 | insidermonkey.comUroGen Pharma sees FY25 operating expenses $215M-$225MMarch 10, 2025 | markets.businessinsider.comUrogen pharma outlines $1B revenue potential for UGN-102 with June 2025 launch targetMarch 10, 2025 | msn.comUroGen Pharma Ltd. (URGN) Q4 2024 Earnings Call TranscriptMarch 10, 2025 | seekingalpha.comSee More Headlines URGN Stock Analysis - Frequently Asked Questions How have URGN shares performed this year? UroGen Pharma's stock was trading at $10.65 at the start of the year. Since then, URGN shares have increased by 11.7% and is now trading at $11.90. View the best growth stocks for 2025 here. How were UroGen Pharma's earnings last quarter? UroGen Pharma Ltd. (NASDAQ:URGN) announced its quarterly earnings results on Monday, March, 10th. The company reported ($0.80) earnings per share for the quarter, missing analysts' consensus estimates of ($0.69) by $0.11. The business had revenue of $24.57 million for the quarter, compared to analysts' expectations of $25.25 million. When did UroGen Pharma IPO? UroGen Pharma (URGN) raised $46 million in an initial public offering (IPO) on Thursday, May 4th 2017. The company issued 3,500,000 shares at $12.00-$14.00 per share. Jefferies and Cowen and Company served as the underwriters for the IPO and Raymond James and Oppenheimer were co-managers. Who are UroGen Pharma's major shareholders? UroGen Pharma's top institutional investors include RTW Investments LP (16.35%), Adage Capital Partners GP L.L.C. (12.49%), Toronto Dominion Bank (7.46%) and Toronto Dominion Bank (7.46%). Insiders that own company stock include Mark Schoenberg and Jason Drew Smith. View institutional ownership trends. How do I buy shares of UroGen Pharma? Shares of URGN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of UroGen Pharma own? Based on aggregate information from My MarketBeat watchlists, some other companies that UroGen Pharma investors own include Voyager Therapeutics (VYGR), AUO (AUOTY), Waste Connections (WCN), American Water Works (AWK), The RMR Group (RMR), DiamondRock Hospitality (DRH) and Triple Flag Precious Metals (TFPM). Company Calendar Last Earnings3/10/2025Today3/24/2025Next Earnings (Estimated)5/12/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:URGN CIK1668243 Webwww.urogen.com Phone(646) 768-9780FaxN/AEmployees200Year FoundedN/APrice Target and Rating Average Stock Price Target$38.20 High Stock Price Target$55.00 Low Stock Price Target$25.00 Potential Upside/Downside+220.7%Consensus RatingBuy Rating Score (0-4)3.17 Research Coverage6 Analysts Profitability EPS (Most Recent Fiscal Year)($3.23) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-102,240,000.00 Net Margins-129.11% Pretax Margin-124.59% Return on EquityN/A Return on Assets-47.94% Debt Debt-to-Equity Ratio4.77 Current Ratio9.00 Quick Ratio8.77 Sales & Book Value Annual Sales$90.40 million Price / Sales6.07 Cash FlowN/A Price / Cash FlowN/A Book Value($2.78) per share Price / Book-4.28Miscellaneous Outstanding Shares46,094,000Free Float22,258,000Market Cap$548.98 million OptionableOptionable Beta1.12 Social Links 5G Stocks: The Path Forward is ProfitableEnter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free Report This page (NASDAQ:URGN) was last updated on 3/24/2025 by MarketBeat.com Staff From Our PartnersThis could put Trump on new $100 billAccording to one of the most connected men in Washington… A surprising new bill was just introduced in Wash...Paradigm Press | SponsoredMost gold “analysts” aren’t really gold analysts… [watch out]People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “g...Golden Portfolio | SponsoredTrump Makes Major Crypto AnnouncementTrump Ends the “War on Crypto” I expect it to pump the market, which is why I'm recommending ONE coin to al...Crypto 101 Media | SponsoredYour Wealth is Under AttackPlease don't wait—this is your moment to take action. Download your Wealth Protection Guide now, claim your fr...American Alternative | SponsoredMusk’s real agenda in D.C. Companies connected to Elon’s new map of America are making major climbs in price. And on May 30, the next wav...Porter & Company | SponsoredCrypto’s crashing…but we’re still profitingMost traders are panicking right now. Bitcoin’s dropping. Altcoins are bleeding. The stock market’s a mess....Crypto Swap Profits | SponsoredAlert: DOGE goes liveElon will most likely be at the helm of it all. And just days from now, could bring about the biggest econo...Altimetry | SponsoredA market crash is coming—here’s whenThe stock market cycle I've used to identify the most likely day of the next market crash is the exact same in...Chaikin Analytics | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding UroGen Pharma Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share UroGen Pharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.